# Clasp Therapeutics

> Clasp Therapeutics, Inc. is a clinical-stage precision immuno-oncology company in Cambridge,
> Massachusetts and Rockville, Maryland, developing next-generation T cell engagers (TCEs) on its
> proprietary pHLAre platform, which redirects T cells to mutant peptides — p53 R175H, mutant KRas —
> presented by specific HLA molecules on tumor cells. Lead candidate CLSP-1025 is in the Phase 1
> GUARDIAN-101 trial (NCT06778863); CLSP-5282, a KRas-directed TCE, was unveiled at AACR 2026.
> Clasp Therapeutics publishes **no public API, developer portal, SDK, or machine-readable
> specification** — its product is a therapeutic, not software.

## Company

- [Homepage](https://www.clasptx.com/): pHLAre platform, pipeline, and company overview.
- [Leadership Team](https://www.clasptx.com/leadership-team): Executive team.
- [Founders](https://www.clasptx.com/founders): Johns Hopkins scientific founders, including Bert Vogelstein, Drew Pardoll, Kenneth Kinzler, Shibin Zhou, Kellie Smith and Nick Papadopoulos.
- [Board of Directors](https://www.clasptx.com/board-of-directors): Board composition.
- [Privacy Policy](https://www.clasptx.com/privacy-policy): Site privacy policy.
- [LinkedIn](https://www.linkedin.com/company/clasp-therapeutics/): Company profile.

## Science and pipeline

- [pHLAre platform](https://www.clasptx.com/): Precision HLA-redirecting T cell engagers targeting tumor-exclusive mutant peptide/HLA complexes.
- CLSP-1025: TCE targeting the p53 R175H mutant peptide presented by HLA-A*02:01; Phase 1 GUARDIAN-101.
- CLSP-5282: First-in-class KRas-directed T cell engager, presented at AACR 2026.
- [GUARDIAN-101 (NCT06778863)](https://clinicaltrials.gov/study/NCT06778863): Phase 1 trial record on ClinicalTrials.gov.

## News and publications

- [Press Releases & Publications](https://www.clasptx.com/press-release-publications): Company announcements, conference presentations and publications.
- [RSS feed](https://www.clasptx.com/press-release-publications?format=rss): Machine-readable feed of the above.

## Contact

- General: info@clasptx.com
- Partnerships: partner@clasptx.com
- Media: media@clasptx.com
- Careers: careers@clasptx.com

## API surface

Clasp Therapeutics has no public API surface. Probed 2026-08-09 against `https://www.clasptx.com`,
all HTTP 404: `/openapi.json`, `/openapi.yaml`, `/swagger.json`, `/v1/openapi.json`, `/api-docs`,
`/docs`, `/redoc`, `/api`, `/graphql`, `/developers`, `/developer`, `/api-documentation`,
`/llms.txt`, `/.well-known/security.txt`, `/.well-known/openid-configuration`,
`/.well-known/oauth-authorization-server`, `/.well-known/api-catalog`, `/.well-known/ai-plugin.json`,
`/.well-known/agent-card.json`, `/.well-known/agent.json`. The site is a Squarespace marketing
site whose 41-URL sitemap covers only leadership, founders, board, press releases and the privacy
policy. The hosts `api.`, `developer.`, `developers.`, `docs.`, `portal.`, `app.`, `status.` and
`trust.clasptx.com` do not resolve in DNS.

## API Evangelist artifacts

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/clasp-therapeutics/refs/heads/main/apis.yml): APIs.json 0.20 profile for Clasp Therapeutics.
- [Domain security](https://raw.githubusercontent.com/api-evangelist/clasp-therapeutics/refs/heads/main/security/clasp-therapeutics-domain-security.yml): Probed TLS, HSTS, DNSSEC, CAA, SPF and DMARC posture.